![]() Alnylam Pharmaceuticals Alnylam is a biopharmaceutical company developing novel therapeutics based on RNA interference, or RNAi. | ![]() Reata Pharmaceuticals Reata Pharmaceuticals is a biopharmaceutical company that develops therapeutics for patients with serious or life-threatening diseases. | ![]() Celyad Celyad is a biopharmaceutical company focused on the discovery and development of regenerative and protective therapies in cardiology and oncology. | ![]() Sorrento Therapeutics Sorrento Therapeutics is focused on the development of proprietary drug therapeutics for addressing unmet medical needs.
| ![]() CureVac CureVac is a biotechnology company that is active in the field of messenger RNA (mRNA) technology. | ![]() Regulus Therapeutics Regulus Therapeutics is a biopharmaceutical company involved in the R&D of high-impact medicines based on microRNAs. | ![]() Sarepta Therapeutics Sarepta Therapeutics is a biopharmaceutical company specializing in the discovery and development of RNA-targeted therapeutics, gene therapy and, other genetic therapeutic modalities for the treatment of rare diseases. | ![]() Ionis Pharmaceuticals Ionis Pharmaceuticals (formerly known as Isis Pharmaceuticals) is a company that discovers and develops RNA-targeted therapeutics. | ||
Founding Date | Founding Date 2002 | Founding Date 2002 | Founding Date 2007 | Founding Date 2006 | Founding Date 2010 | Founding Date 2000 | Founding Date 2007 | Founding Date 1980 | Founding Date 1989 |
Type | Type Public | Type Public | Type Public | Type Public | Type Public | Type Private | Type Public | Type Public | Type Public |
Tags | |||||||||
Locations | Locations Plano, US HQ Irving, US Plano, US | Locations Mont-Saint-Guibert, BE HQ New York, US | Locations San Diego, US HQ San Diego, US | Locations Cambridge, US HQ Norwood, US | Locations Tübingen, DE HQ Frankfurt Am Main, DE Tübingen, DE Boston, US | Locations San Diego, US HQ | Locations Cambridge, US HQ Dublin, IE Zug, CH Providence, US | Locations Carlsbad, US HQ | |
Employees | Employees 1,32324% increase | Employees 22079% increase | Employees 95 | Employees 31019% decrease | Employees 2,700108% increase | Employees 4004% increase | Employees 2462% decrease | Employees 8403% decrease | Employees 7577% decrease |
Valuation ($) | Valuation ($) 27.7 b | Valuation ($) 1.4 b | Valuation ($) 28.3 m | Valuation ($) 309.4 m | Valuation ($) 78.3 b | Valuation ($) 1.5 b | Valuation ($) 223.3 m | Valuation ($) 10.7 b | Valuation ($) 5.6 b |
Twitter followers | Twitter followers 16 k | Twitter followers 1.3 k | Twitter followers 2.4 k | Twitter followers N/A | Twitter followers 151 k | Twitter followers 10 | Twitter followers 808 | Twitter followers 4.6 k | Twitter followers 4.3 k |
Number of tweets (last 30 days) | Number of tweets (last 30 days) 27 | Number of tweets (last 30 days) 6 | Number of tweets (last 30 days) N/A | Number of tweets (last 30 days) N/A | Number of tweets (last 30 days) 30 | Number of tweets (last 30 days) N/A | Number of tweets (last 30 days) N/A | Number of tweets (last 30 days) 7 | Number of tweets (last 30 days) 8 |
Average likes per tweet (last 30 days) | Average likes per tweet (last 30 days) 9.1 | Average likes per tweet (last 30 days) 2.3 | Average likes per tweet (last 30 days) N/A | Average likes per tweet (last 30 days) N/A | Average likes per tweet (last 30 days) 33.3 | Average likes per tweet (last 30 days) N/A | Average likes per tweet (last 30 days) N/A | Average likes per tweet (last 30 days) 10.1 | Average likes per tweet (last 30 days) 6.4 |
Percentage of tweets with engagement (last 30 days) | Percentage of tweets with engagement (last 30 days) 100% | Percentage of tweets with engagement (last 30 days) 100% | Percentage of tweets with engagement (last 30 days) N/A | Percentage of tweets with engagement (last 30 days) N/A | Percentage of tweets with engagement (last 30 days) 100% | Percentage of tweets with engagement (last 30 days) N/A | Percentage of tweets with engagement (last 30 days) N/A | Percentage of tweets with engagement (last 30 days) 71.43% | Percentage of tweets with engagement (last 30 days) 100% |
Alexa Website Rank | Alexa Website Rank 376993 | Alexa Website Rank 267230 | Alexa Website Rank 460272 | Alexa Website Rank 412753 | Alexa Website Rank 288967 | Alexa Website Rank 457967 | Alexa Website Rank 181560 | Alexa Website Rank 448530 | Alexa Website Rank 333062 |
Employee Rating | Employee Rating 4.2 | Employee Rating 3.6 | Employee Rating 3.5 | Employee Rating 3.4 | Employee Rating 3.7 | Employee Rating 3.2 | Employee Rating 2.8 | Employee Rating 4.1 | Employee Rating 3.6 |
Financial | |||||||||
Revenue (est.) | Revenue (est.) $844.3m (FY, 2021) | Revenue (est.) $11.5m (FY, 2021) | Revenue (est.) N/A | Revenue (est.) $52.9m (FY, 2021) | Revenue (est.) $18.5b (FY, 2021) | Revenue (est.) €12.6m (FY, 2018) | Revenue (est.) N/A | Revenue (est.) $701.9m (FY, 2021) | Revenue (est.) $810.5m (FY, 2021) |
Cost of goods | Cost of goods $115m (FY, 2021) | Cost of goods N/A | Cost of goods N/A | Cost of goods N/A | Cost of goods $2.6b (FY, 2021) | Cost of goods €22.3m (FY, 2018) | Cost of goods N/A | Cost of goods $97m (FY, 2021) | Cost of goods $10.8m (FY, 2021) |
Gross profit | Gross profit N/A | Gross profit N/A | Gross profit €5.8m (FY, 2021) | Gross profit N/A | Gross profit $15.9b (FY, 2021) | Gross profit (€9.8m) (FY, 2018) | Gross profit N/A | Gross profit $604.8m (FY, 2021) | Gross profit N/A |
Net income | Net income ($852.8m) (FY, 2021) | Net income ($297.4m) (FY, 2021) | Net income (€26.5m) (FY, 2021) | Net income ($429.1m) (FY, 2021) | Net income $12.2b (FY, 2021) | Net income (€74.6m) (FY, 2018) | Net income ($27.8m) (FY, 2021) | Net income ($418.8m) (FY, 2021) | Net income ($28.6m) (FY, 2021) |
Operating ⚠ | |||||||||
Patent Applications | Patent Applications N/A | Patent Applications N/A | Patent Applications N/A | Patent Applications N/A | Patent Applications 430 (FY, 2021) | Patent Applications 500 (Mar, 2020) | Patent Applications N/A | Patent Applications N/A | Patent Applications N/A |
Patents (US) | Patents (US) N/A | Patents (US) N/A | Patents (US) N/A | Patents (US) N/A | Patents (US) 170 (FY, 2021) | Patents (US) N/A | Patents (US) N/A | Patents (US) N/A | Patents (US) 161 (Jun, 2021) |
Patents Issued | Patents Issued N/A | Patents Issued 240 (FY, 2016) | Patents Issued N/A | Patents Issued N/A | Patents Issued 270 (FY, 2020) | Patents Issued 233 (May, 2020) | Patents Issued 300 (FY, 2016) | Patents Issued N/A | Patents Issued N/A |
Phase I Trials Products | Phase I Trials Products N/A | Phase I Trials Products 2 (FY, 2016) | Phase I Trials Products N/A | Phase I Trials Products N/A | Phase I Trials Products N/A | Phase I Trials Products 3 (May, 2020) | Phase I Trials Products N/A | Phase I Trials Products N/A | Phase I Trials Products 6 (FY, 2020) |
Phase II Trials Products | Phase II Trials Products N/A | Phase II Trials Products 4 (FY, 2016) | Phase II Trials Products N/A | Phase II Trials Products N/A | Phase II Trials Products N/A | Phase II Trials Products N/A | Phase II Trials Products N/A | Phase II Trials Products N/A | Phase II Trials Products 24 (FY, 2020) |
Phase III Trials Products | Phase III Trials Products N/A | Phase III Trials Products 1 (FY, 2016) | Phase III Trials Products N/A | Phase III Trials Products N/A | Phase III Trials Products N/A | Phase III Trials Products N/A | Phase III Trials Products N/A | Phase III Trials Products N/A | Phase III Trials Products 6 (FY, 2020) |
Funding | |||||||||
Total funding raised | Total funding raised $ 1.5b | Total funding raised $ 468.9m | Total funding raised N/A | Total funding raised $ 42.6m | Total funding raised $ 1.8b | Total funding raised $ 1.1b | Total funding raised $ 10m | Total funding raised N/A | Total funding raised N/A |
Reata Pharmaceuticals is a biopharmaceutical company that develops therapeutics for patients with serious or life-threatening diseases.
View companyCelyad is a biopharmaceutical company focused on the discovery and development of regenerative and protective therapies in cardiology and oncology.
View companySorrento Therapeutics is focused on the development of proprietary drug therapeutics for addressing unmet medical needs.
View companyModerna is a biotechnology company that develops therapeutics and vaccines.
View company